Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 10/20 | 0.68 |
| ▸ | CD40 | P25942 | 1/20 | 0.60 |
| ▸ | CD40LG | P29965 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TIMP3 | P35625 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338412 | 0.98 | CCR8 (0.70) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL1339026 | 0.91 | NPC1 (0.62) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL6242899 | 0.89 | CCR8 (0.58) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL14215479 | 0.85 | CCR8 (0.68) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL1338666 | 0.85 | CCR8 (0.68) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL12919715 | 0.84 | TIMP3 (0.56) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL11782093 | 0.84 | HSD17B10 (0.56) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL4108474 | 0.84 | CCR8 (0.67) | CCR8CD40CD40LGNPC1CYP1A2 | |
| SCHEMBL6120265 | 0.82 | CD40 (0.50) | CCR8CD40CD40LGCYP1A2TIMP3 | |
| SCHEMBL1413171 | 0.82 | AURKB (0.52) | CCR8CD40CD40LGNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | ITALFARMACO, S. A. (ES) | 2009-03-19 | — | — | US | claimed |
| EP-1994929-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2008-11-26 | — | — | EP | claimed |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | ITALFARMACO, S.A. (ES) | 2006-07-20 | — | — | US | claimed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | claimed |
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | ITALFARMACO, S. A. (ES) | 2009-03-19 | — | — | US | disclosed |
| EP-1994929-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2008-11-26 | — | — | EP | disclosed |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | ITALFARMACO, S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | NQO2, SQLE, SQOR | CCR8 4773/4885CD40 2893/4885CD40LG 4058/4885 |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | SUCNR1, NR1H4, CYP2B6 | CCR8 580/4885CD40 2518/4885CD40LG 3370/4885 |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | SUCNR1, NR1H4, CYP2B6 | CCR8 545/4885CD40 2564/4885CD40LG 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.